Home » Topics » BioWorld Science

BioWorld Science
RSS

Lidak reacquires certain rights to Lidakol from BMS

Dec. 2, 1996

Expanded patent portfolio for Dyax technology

Dec. 2, 1996

Ivermectin approved for use in humans

Dec. 2, 1996

SuperGen-Galenica anticancer drug collaboration

Dec. 2, 1996

Axcan-Schwarz joint venture to market URSO

Dec. 2, 1996

Merck & Co. describes lipid A biosynthesis inhibitor with antibacterial activity

Dec. 2, 1996

New anxiolytic under development at Parke-Davis

Dec. 2, 1996

Antiepileptic agent reported by Parke-Davis

Dec. 2, 1996

Antiproliferative agents disclosed by Kitasato Institute

Dec. 2, 1996

Antihyperlipidemic agents from natural source described by Takeda

Dec. 2, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...